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Background/Purpose: Stroke recurrence in the acute phase is not rare, even in minor stroke patients. We
investigated whether combined antithrombotic therapy with early oral cilostazol prevents progressive
stroke and improves outcomes in ischemic stroke patients.
Methods: For the present study, 311 ﬁrst-time stroke patients who were admitted within 48 hours after
the onset and were diagnosed as having a noncardioembolic stroke with National Institutes of Health
Stroke Scale (NIHSS) scores of  7 were prospectively included. All patients were classiﬁed into two
groups according to oral cilostazol. In Group A, 154 patients were treated with conventional antith-
rombotic agents with or without oral aspirin (100e200 mg/d), during the ﬁrst 7 hospital days. In Group
C, 157 patients were treated with oral cilostazol 200 mg/d (100 mg twice daily) plus conventional
antithrombotic agents during the ﬁrst 7 hospital days. Neurological deterioration during the ﬁrst 21 days,
stroke recurrence, cardiovascular events, and any deaths during a 3-month follow-up period were
compared between Groups A and C.
Results: The frequencies of neurological deterioration, stroke recurrence, acute myocardial infarction, or
death from all causes did not differ between Groups A and C. A good outcome at 3 months after
admission was observed more frequently in Group C than in Group A patients (68% vs. 56%, p ¼ 0.0253).
In the multivariate analysis, age [odds ratio (OR), 0.94; 95% conﬁdence interval (CI), 0.91e0.97;
p < 0.0001] and initial NIHSS score (OR, 0.65; 95% CI, 0.56e0.76; p < 0.0001) were negatively associated,
and cilostazol (OR, 1.99; 95% CI, 1.05e3.77; p ¼ 0.0353) was positively associated with a good outcome.
Conclusion: In noncardioembolic stroke, combined antithrombotic therapy with early oral cilostazol in
the acute phase appears to be associated with a good outcome in patients with progressive stroke.
Copyright © 2015, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
An ischemic stroke with a low initial National Institutes of
Health Stroke Scale (NIHSS) score, that is a minor stroke, is usually
considered to have a good outcome. Nedeltchev et al1 reported that
75% of patients with a minor stroke had a favorable outcome after
3 months. By contrast, several studies demonstrated thatular Medicine, Stroke Center,
ahatahigashi-ku, Kitakyushu,
imoto).
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d/4.0/).neurological deterioration or stroke recurrence in the acute phase
(progressive stroke) is not rare, even in minor stroke patients.2,3
In accordancewith the subtype of ischemic stroke, patients with
large artery atherosclerosis or a deep perforating artery infarct
often show acute neurological deterioration or a progressive motor
deﬁcit.4e8 Furthermore, a deep perforating artery infarct caused by
an atherothrombotic process at the origin or the proximal portion
of a major cerebral artery, which is called branch atheromatous
disease, is considered to be associated with a particularly high risk
for progressive stroke.9e11 In Japan, such stroke patients are usually
treated with oral aspirin, intravenous ozagrel sodium (throm-
boxane A2 inhibitor), or argatroban hydrate (thrombin inhibitor) inlished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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rombotic agents is insufﬁcient for preventing progressive stroke.
In the Japanese aging society, safety of antiplatelet therapy
should be emphasized as well as effectiveness, because bleeding
events with antiplatelet therapy are not rare. Toyoda et al15
revealed that bleeding was more frequent in dual than single
antithrombotic therapy. By contrast, a randomized trial demon-
strated that dual antiplatelet therapy (DAPT) with aspirin and clo-
pidogrel in the acute phase of minor stroke was beneﬁcial and
safe.16 In a previous Japanese study, combined therapy including
oral cilostazol improved the outcome of acute larger lacunar-type
infarction patients.17 Cilostazol is an antiplatelet agent that also
causes vasodilation by increased production of nitric oxide,18 and it
inhibits smooth muscle proliferation and inﬂammation.19,20 The
second Cilostazol Stroke Prevention Study (CSPS2) proved that
cilostazol was superior to aspirin for the secondary prevention of
stroke in the subacute or chronic phase of noncardioembolic
ischemic stroke.21
The purpose of the present preliminary study was to investigate
whether combined antithrombotic therapy in the acute phase of
minor stroke including oral cilostazol and conventional antith-
rombotic agents, such as aspirin, ozagrel sodium, or argatroban
prevents progressive strokes and improves outcomes.
2. Methods
2.1. Patients
For the present study, from April 2009 to March 2013, among
1089 stroke patients, 311 noncardioembolic ischemic stroke (Trial
of org 10172 in acute stroke treatment (TOAST) classiﬁcation22)
patients who were admitted to the Stroke Center, Steel Memorial
Yawata Hospital, (Kitakyushu, Japan) within 48 hours from symp-
tom onset with an initial NIHSS score of  7 and a prestroke
modiﬁed Rankin scale (mRS) score of 0 or 1 were prospectively
included. Among the 1089 patients, 456 patients admitted after 48
hours from the onset, 143 patients with an initial NIHSS score of > 7
ormRS score of 2,115 patients withmoderate or high risk sources
for cardioembolism in the TOAST classiﬁcation, 34 patients treated
with antithrombotic agents other than cilostazol, aspirin, ozagrel
sodium, and argatroban, and 30 patients with prior symptomatic
coronary diseasewere excluded in order. All patients gave informed
consent to be included into the present study which was approved
by the local ethical committee.
In the study period, from January 1, 2011 to September 30, 2012,
157 patients were treated with oral cilostazol 200 mg/d (100 mg
twice daily) plus conventional antithrombotic agents: intravenous
ozagrel sodium (160 mg/d), or argatroban (60 mg/d during the
initial 48 hours and 20 mg/d during the following 5 days) with or
without oral aspirin (100e200 mg/d), during the ﬁrst 7 hospital
days (Group C). After initial treatment, only oral cilostazol was
continued. The other 154 patients, admitted from April 1, 2009 to
December 31, 2010 and from October 1, 2012 to March 31, 2013
were treated only with conventional antithrombotic agents during
the ﬁrst 3e14 hospital days (Group A). After the initial treatment,
any single antiplatelet agent was used. The choice between ozagrel
sodium and argatroban and the decision to use aspirin were left to
each attending doctor. All patients were treated at the stroke unit.
2.2. Clinical evaluations
For all patients, infarcts were identiﬁed using magnetic reso-
nance imaging (MRI) studies including diffusion-weighed imaging
(DWI), and vascular lesions were evaluated using both MR angi-
ography and duplex carotid ultrasonography. MRI studies wereperformed for all patients on the 1st hospital day. The MRI appa-
ratus was a 1.5-T MR (Philips, Andover, MA, USA) unit with echo
planar capability. DWI was performed simultaneously using a
multislice, single-shot, spin echo planar imaging sequence. Diffu-
sion gradients were applied in each of the x-, y-, and z-axes with
two b values (0 s/mm2 and 1000 s/mm2). A focal hyperintensity on
DWI was deﬁned as an acute infarct.
Stroke subtypes were evaluated by the TOAST classiﬁcation. A
diagnosis of diabetes mellitus was determined by the diagnostic
criteria of the Japan Diabetes Society (JDS) in the chronic stage or
based on a medical history of diabetes. Hypertension was deﬁned
as a systolic blood pressure  140 mmHg or a diastolic pressure 
90 mmHg in the chronic stage, or current treatment with antihy-
pertensive drugs. Dyslipidemia was deﬁned as one of a low density
lipoprotein (LDL) cholesterol level  140 mg/dL, high density li-
poprotein (HDL) cholesterol level < 40 mg/dL,
triglycerides  150 mg/dL, or current treatment with a cholesterol-
lowering drug. Atrial ﬁbrillation was diagnosed based on electro-
cardiographic ﬁndings on admission or during hospitalization.
The NIHSS score was assessed on admission and at 48 hours, 7
days, and 21 days after admission. NIHSS score worsening by  1
point was deﬁned as neurological deterioration. Stroke recurrence
was deﬁned as neurological deteriorationwith a new ischemic lesion
on DWI. An mRS score of 0 or 1 was deﬁned as a good outcome.
Neurological deterioration during the ﬁrst 21 days, stroke
recurrence, cardiovascular events, and any deaths during a 3-
month follow-up period were compared between Group A and
Group C. Clinical factors associated with a good outcome were also
investigated.
2.3. Data analysis
Statistical analyses were performed using the JMP version 9
software program (SAS Institute Inc., Cary, NC, USA). On univariate
analysis, the Chi-square test and paired t test were used. In the
multivariate analysis, multivariate-adjusted odds ratios (ORs) and
95% conﬁdence intervals (CIs) for each study outcome were esti-
mated by logistic regression analysis. A two-tailed probability
p < 0.05 was considered to indicate a signiﬁcant difference.
3. Results
3.1. Background characteristics and clinical course
There were no signiﬁcant differences in background character-
istics, stroke subtype (TOAST classiﬁcation), and conventional
antithrombotic agents between Group A and Group C (Table 1).
Although there were no differences in the NIHSS scores between
the two groups on admission, 48 hours, and 7 days after admission,
the NIHSS score 21 days after admission was signiﬁcantly lower in
Group C (2.0 ± 2.3) than in Group A (2.8 ± 2.4, p ¼ 0.0016; Table 2,
Figure 1).
The frequencies of neurological deterioration, stroke recurrence,
acute myocardial infarction, or death from all causes did not differ
between Group A and Group C (Table 2). One patient in Group C had
a fatal myocardial infarction 4 days after admission. One patient in
Group A had fatal pneumonia 14 days after admission. A fatal stroke
recurrence occurred in two patients in Group C and in one patient
in Group A during the observation period. No patients in either
group developed symptomatic intracranial hemorrhagic trans-
formation or other major bleeding.
A good outcome was relatively more frequent at 21 days after
admission (62% vs. 51%, p¼ 0.0622) and signiﬁcantly more frequent
at 3 months after admission (68% vs. 56%, p ¼ 0.0253) in Group C
than in Group A (Table 2). In patients with neurological
Table 1
Clinical characteristics and treatment in the acute phase in Groups A and C.
Group C Group A p
n ¼ 157 n ¼ 154
Age (y) 71.9 ± 10.6 72.1 ± 10.8 0.8661
Male 99 (63%) 87 (56) 0.2378
Hypertension 126 (80%) 129 (84%) 0.8661
Diabetes mellitus 72 (46%) 70 (45%) 0.9428
Dyslipidemia 75 (48%) 74 (48%) 0.9604
Systolic blood pressure (mmHg) 160.5 ± 26.0 156.8 ± 23.9 0.1891
Diastolic blood pressure (mmHg) 85.3 ± 15.3 86.0 ± 20.0 0.7017
Glucose (mg/dL) 142.6 ± 53.7 132.0 ± 42.6 0.0556
HbA1c (%) 6.22 ± 1.46 5.98 ± 1.30 0.1244
LDL cholesterol (mg/dL) 129.3 ± 34.8 133.1 ± 31.5 0.3341
HDL cholesterol (mg/dL) 53.3 ± 14.9 54.2 ± 18.3 0.6156
Cerebral artery occlusive disease of 50% or more in diameter 49 (31) 53 (34%) 0.5472
Trial of org 10172 in acute stroke treatment (TOAST) classiﬁcation 0.4499
Small vessel occlusion 38 (24%) 40 (26%)
Large artery atherosclerosis 43 (27) 46 (30%)
Others 76 (49) 68 (44%)
Branch atheromatous disease 25 (16%) 17 (11%)
Infarct size
 15 mm in diameter 102 (65%) 93 (60%) 0.4038
Treatment after admission
Ozagrel sodium 114 (73%) 104 (68%) 0.3280
Argatroban hydrate 30 (19%) 40 (26%) 0.1472
Aspirin 122 (78%) 115 (75%) 0.7742
Edaravone 89 (57%) 98 (64%) 0.2108
Statin 62 (39%) 59 (38%) 0.8312
HbA1c ¼ hemoglobin A1c; HDL ¼ high density lipoprotein; LDL ¼ low density lipoprotein.
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frequent in Group C (12 of 32, 38%) than in Group A (4 of 39, 10%,
p ¼ 0.0166).
Changes in the NIHSS score were not signiﬁcantly different be-
tween the two groups with neurological deterioration (Figure 2). In
Group C, a peak in the NIHSS score was observed 48 hours after
admission, and the score returned to the initial level 21 days after
admission. In comparison with Group A, the peak in the NIHSS
score occurred earlier and the score 21 days after admission was
relatively lower in Group C (4.7 ± 3.6 vs. 5.5 ± 2.3, p ¼ 0.0645).
All patients in both groups completed the initial 7-day treat-
ment. In eight patients in Group C and seven patients in Group A,
cilostazol was discontinued due to headache, tachycardia, or pal-
pitations after initial treatment. In those patients, clopidogrel was
used instead. Paroxysmal atrial ﬁbrillation was seen in one Group C
patient 10 days after admission. Cilostazol was discontinued, and
warfarin was administered.Table 2
Clinical course in Groups A and C.
Group C Group A p
n ¼ 157 n ¼ 154
NIHSS score
On admission 3.6 ± 2.2 3.6 ± 1.7 0.9240
48 h 3.2 ± 3.1 3.5 ± 2.4 0.2809
7 d 2.7 ± 2.6 3.2 ± 2.7 0.0994
21 d 2.0 ± 2.3 2.8 ± 2.4 0.0016
Neurological deterioration within 21 d 32 (20%) 39 (25%) 0.2992
Stroke recurrence 8 (5.1%) 11 (7.1%) 0.4510
Cardiovascular event 1 (0.6%) 0 d
Myocardial infarction 1 (0.6%) 0 d
All-cause death 3 (1.9%) 2 (1.3%) 0.6678
Pneumonia 8 (5.1%) 11 (7.1%) 0.4510
mRS score 0e1
21 d 97 (62%) 79 (51%) 0.0622
3 mo 107 (68%) 86 (56%) 0.0253
mRS ¼ modiﬁed Rankin scale; NIHSS ¼ National Institutes of Health Stroke Scale.3.2. Clinical factors for a good outcome
Of the 311 patients, 193 showed a good outcome 3 months after
admission. Table 3 shows a comparison between patients with and
without a good outcome. Patients with a good outcome were
signiﬁcantly younger than those without a good outcome
(69.3 ± 10.2 years vs. 76.3 ± 10.0 years, p < 0.0001). Diabetes
mellitus was relatively less frequent (42% vs. 52%, p ¼ 0.0947), and
major cerebral artery occlusive disease of  50% in diameter was
signiﬁcantly less frequent (24% vs. 47%, p < 0.0001) in patients with
than without a good outcome. The initial NIHSS score wasFigure 1. Changes in the National Institutes of Health Stroke Scale (NIHSS) score in
Group C and Group A patients. There is no signiﬁcant difference in the changes in the
NIHSS score between Group C and Group A (p ¼ 0.1466). Although there is no dif-
ference in the NIHSS score between the two groups on admission, 48 hours, and 7 days
after admission, the score 21 days after admission is signiﬁcantly lower in Group C
than in Group A (2.0 ± 2.3 vs. 2.8 ± 2.4, p ¼ 0.0016).
Figure 2. Changes in the National Institutes of Health Stroke Scale (NIHSS) score in
patients with neurological deterioration within 21 days after admission. There is no
signiﬁcant difference between Group C and Group A (p ¼ 0.8334). However, the NIHSS
score 21 days after admission is relatively lower in Group C than in Group A patients
with neurological deterioration (4.7 ± 3.6 vs. 5.5 ± 2.3, p ¼ 0.0645).
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neurological deterioration (8.3% vs. 47%, p < 0.0001), stroke
recurrence (0.5% vs. 15%, p < 0.0001), and pneumonia (2.6% vs. 12%,
p ¼ 0.0009) were signiﬁcantly less frequent in patients with than
without a good outcome. The initial LDL cholesterol
(122.7 ± 32.4 mg/dL vs. 136.1 ± 34.0 mg/dL, p ¼ 0.0253) and
hemoglobin A1c (5.97% ± 1.20% vs. 6.31% ± 1.62%, p ¼ 0.0385)
values were signiﬁcantly lower, and the initial systolic blood
pressure (156.8 ± 25.9 mmHg vs. 161.8 ± 23.3 mmHg, p ¼ 0.0860)
on admission was relatively lower in patients with than without a
good outcome.
A logistic regression analysis with cilostazol, age, initial NIHSS
score, major cerebral artery occlusive disease, LDL cholesterol,
HbA1c, systolic blood pressure, neurological deterioration, andTable 3
Clinical characteristics of patients with and without a good outcome.
mR
n ¼
Age (y) 69.
Male 120
Hypertension 159
Diabetes mellitus 81
Dyslipidemia 88
Systolic blood pressure (mmHg) 156
Diastolic blood pressure (mmHg) 85.
Glucose (mg/dL) 139
HbA1c (%) 5.9
LDL cholesterol (mg/dL) 127
HDL cholesterol (mg/dL) 54.
Cerebral artery occlusive disease of 50% or more in diameter 47
NIHSS score on admission 2.9
Infarct size
 15 mm diameter 124
Antithrombotic agents
Cilostazol 107
Ozagrel sodium 138
Argatroban hydrate 39
Aspirin 152
Neurological deterioration within 21 d 16
Stroke recurrence 1 (
Pneumonia 5 (
HbA1c ¼ hemoglobin A1c; HDL ¼ high density lipoprotein; LDL ¼ low density lipoprotepneumonia, showed that age (OR, 0.94; 95% CI, 0.91e0.97;
p < 0.0001), initial NIHSS score (OR, 0.65; 95% CI, 0.56e0.76;
p < 0.0001), and neurological deterioration (OR, 0.07; 95% CI,
0.03e0.18; p < 0.0001) were negatively associated, and cilostazol
(OR, 1.99; 95% CI, 1.05e3.77; p ¼ 0.0353) was positively associated
with a good outcome.4. Discussion
Previous studies and the present study proved that neurological
deterioration in the acute phase of ischemic strokewas a signiﬁcant
negative predictor for a good outcome.23e25 In the present study,
42% of the included patients had large artery atherosclerosis or
branch atheromatous disease, which are associated with a high risk
for acute neurological deterioration, and combined antithrombotic
therapy including oral cilostazol could not reduce neurological
deterioration, stroke recurrence, and mortality. However, com-
bined therapy increased the rate of a good outcome 3 months after
admission. With regard to changes in the NIHSS score in patients
with neurological deterioration, the peak and improvement of the
score occurred earlier in Group C than in Group A. Moreover, a good
outcome with respect to neurological deterioration was more
frequent in Group C than in Group A. Cilostazol might facilitate
recovery from neurological deterioration.
Immediate and appropriate medical treatment is important
even in patients with a transient ischemic attack (TIA) or minor
stroke.26 Several studies have demonstrated the effect of DAPT in
the acute phase of a minor stroke or TIA. The Clopidogrel in High-
Risk Patients with Acute Nondisabling Cerebrovascular Events
(CHANCE) trial revealed the beneﬁt of DAPT as an acute treatment
for a minor stroke and TIA.15 The Fast Assessment of Stroke and
Transient ischemic attack to prevent Early Recurrence (FASTER)
trial and the clopidogrel plus aspirin versus aspirin alone for
reducing embolization in patients with acute symptomatic cerebral
or carotid artery stenosis (CLAIR) study also demonstrated com-
bined therapy with aspirin plus clopidogrel might bemore effective
for preventing stroke or a cardiovascular event in comparison withS score 0e1 mRS score 2e6 p
193 n ¼ 118
3 ± 10.2 76.3 ± 10.0 < 0.0001
(62%) 66 (56%) 0.2758
(82%) 96 (81%) 0.8190
(42%) 61 (52%) 0.0947
(46%) 61 (52%) 0.2961
.8 ± 25.9 161.8 ± 23.3 0.0860
0 ± 17.1 86.6 ± 18.7 0.4338
.9 ± 50.7 133.3 ± 45.4 0.2493
7 ± 1.20 6.31 ± 1.62 0.0385
.7 ± 32.4 136.1 ± 34.0 0.0253
6 ± 15.0 52.4 ± 18.7 0.2561
(24%) 55 (47%) < 0.0001
± 1.9 4.7 ± 2.2 < 0.0001
(64%) 71 (60%) 0.4704
(55%) 50 (42%) 0.0253
(72%) 80 (68%) 0.4885
(20%) 31 (26%) 0.2141
(79%) 85 (72%) 0.4778
(8.3%) 55 (47%) <0.0001
0.5%) 18 (15%) <0.0001
2.6%) 14 (12%) 0.0009
in; NIHSS ¼ National Institutes of Health Stroke Scale.
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and CLAIR demonstrated that early DAPT is likely to be effective and
safe, and a combinationwith aspirin plus clopidogrel was themajor
strategy in most studies.29
By contrast, the antiplatelet effect of clopidogrel may be less in
Japanese patients, perhaps due to the effect of the CYP4502C19 ge-
netic polymorphism.30,31 Furuta et al32 reported that 20% of Japanese
exhibited little CYP2C19 activity compared with only 2.5% of Cau-
casians. Moreover, DAPT with aspirin plus clopidogrel is known as a
risk for major or intracranial bleeding.33 Therefore, a new strategy
other than aspirin plus clopidogrel is required for the Japanese aging
society where the number of stroke patients is increasing, and cil-
ostazol may be useful as a drug for such combined therapy.
CSPS2 proved that cilostazol was superior to aspirin for the sec-
ondary prevention of stroke in the subacute or chronic phase of
noncardioembolic stroke.21 Unfortunately, there are few studies of
the efﬁcacy of antithrombotic therapy with cilostazol in the acute
phase of ischemic stroke. A Japanese pilot study reported that pa-
tients treated with aspirin plus cilostazol during the acute phase of
stroke had less neurological deterioration and more favorable out-
comes than those treatedwith aspirin alone.34 Cilostazol hasnot only
an antiplatelet effect, but also vasodilating, endothelial protection,
and antiinﬂammatory effects.18e20 These multiple effects might
contribute to improvement after neurological deterioration in the
present study, although which role is most effective among those
pleiotropic effects is unknown. InCSPS2, cilostazol hada signiﬁcantly
lower risk for bleeding than aspirin.21 In the present study, therewas
also no major bleeding including intracranial hemorrhage. In these
respects, cilostazol is suitable for inclusion in acute combined
antithrombotic therapy, especially in the Japanese aging society.
The present study had several limitations. This was not a ran-
domized study, and conventional antithrombotic agents, aspirin,
ozagrel sodium, and argatroban hydrate, were not controlled.
Moreover, the sample size was too small to prove the absolute ef-
ﬁcacy of cilostazol for preventing neurological deterioration or
stroke recurrences and improving the outcome. A randomized
study of cilostazol in combined antithrombotic treatment during
the acute phase of ischemic stroke should be considered.
In conclusion, combined antithrombotic therapy with oral cil-
ostazol in the acute phase of noncardioembolic stroke did not reduce
the rate of neurological deterioration or stroke recurrence, however,
combined therapy was more strongly associated with a good
outcome 3months after admission than conventional therapy alone.
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